Market Overview

Singular Research Drops Coverage on BioSante Pharma After LibGel Results


In the report, Singular Research writes, "BioSante Pharmaceuticals (NASDAQ: BPAX) LibiGel® performed as expected, but a very strong placebo effectresulted in no statistically significant advantage for LibiGel®.We view this as a display of “mind over matter” fromnurturing women in the trial. Minimally, another clinical trial isnecessary for FDA approval; other new compounds in pipeline areseveral years from approval."

BioSante Pharmaceuticals closed today at $0.44, down 7.08% from market open.

Posted-In: LibGel Singular ResearchAnalyst Color Analyst Ratings


Related Articles (BPAX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's M&A Chatter for Friday December 16, 2011

Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition